Alan Abboud, Amin Tajerian, Sharon Charles, Michael Clores, Marc Goldschmidt, Olga Aroniadis, Andreas Kalogeropoulos
{"title":"Colorectal cancer in heart transplant recipients: A competing risk analysis.","authors":"Alan Abboud, Amin Tajerian, Sharon Charles, Michael Clores, Marc Goldschmidt, Olga Aroniadis, Andreas Kalogeropoulos","doi":"10.1111/eci.70107","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Data on colorectal cancer (CRC) risk in heart transplant (HT) patients are limited, and screening recommendations specific to this population, especially patients under age 45, are lacking. We aimed to assess the incidence of post-HT CRC, with a focus on the effect of age.</p><p><strong>Methods: </strong>Using data from the TriNetX Research Network, we identified 4516 adults (≥18 years) who received HT between 1996 and 2024 in the United States, based on CPT codes for HT (33945) and combined lung-HT (33935). CRC was identified from ICD-10 CM codes (C18, C19, & C20). Because mortality was higher than CRC risk, we used a competing risks framework to estimate CRC incidence.</p><p><strong>Results: </strong>After a median follow-up of 3.6 years (25th-75th percentile, 1.4-6.7), 48 patients developed CRC. Median time from HT to CRC was 4.5 years (.7-8.0). The cumulative incidence of CRC was 1.73% (CI: 1.22%-2.45%) at 10 years, corresponding to 173/100,000 person-years. In comparison, the United States age-adjusted general population rate was 36.5/100,000 between 2016 and 2020. Age at HT was not significantly associated with CRC risk (p = .22); patients age < 45 at HT experienced similar risk as patients ≥45. The CRC risk difference between men and women was not significant (1.89% vs. 1.23% at 10 years; p = .74). All-cause mortality was 20.4% at 5 years and 38.8% at 10 years.</p><p><strong>Conclusions: </strong>In this HT cohort, CRC risk was markedly higher compared to the general population and did not differ by age, suggesting that HT recipients may require screening for CRC regardless of age.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":" ","pages":"e70107"},"PeriodicalIF":3.6000,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/eci.70107","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Data on colorectal cancer (CRC) risk in heart transplant (HT) patients are limited, and screening recommendations specific to this population, especially patients under age 45, are lacking. We aimed to assess the incidence of post-HT CRC, with a focus on the effect of age.
Methods: Using data from the TriNetX Research Network, we identified 4516 adults (≥18 years) who received HT between 1996 and 2024 in the United States, based on CPT codes for HT (33945) and combined lung-HT (33935). CRC was identified from ICD-10 CM codes (C18, C19, & C20). Because mortality was higher than CRC risk, we used a competing risks framework to estimate CRC incidence.
Results: After a median follow-up of 3.6 years (25th-75th percentile, 1.4-6.7), 48 patients developed CRC. Median time from HT to CRC was 4.5 years (.7-8.0). The cumulative incidence of CRC was 1.73% (CI: 1.22%-2.45%) at 10 years, corresponding to 173/100,000 person-years. In comparison, the United States age-adjusted general population rate was 36.5/100,000 between 2016 and 2020. Age at HT was not significantly associated with CRC risk (p = .22); patients age < 45 at HT experienced similar risk as patients ≥45. The CRC risk difference between men and women was not significant (1.89% vs. 1.23% at 10 years; p = .74). All-cause mortality was 20.4% at 5 years and 38.8% at 10 years.
Conclusions: In this HT cohort, CRC risk was markedly higher compared to the general population and did not differ by age, suggesting that HT recipients may require screening for CRC regardless of age.
期刊介绍:
EJCI considers any original contribution from the most sophisticated basic molecular sciences to applied clinical and translational research and evidence-based medicine across a broad range of subspecialties. The EJCI publishes reports of high-quality research that pertain to the genetic, molecular, cellular, or physiological basis of human biology and disease, as well as research that addresses prevalence, diagnosis, course, treatment, and prevention of disease. We are primarily interested in studies directly pertinent to humans, but submission of robust in vitro and animal work is also encouraged. Interdisciplinary work and research using innovative methods and combinations of laboratory, clinical, and epidemiological methodologies and techniques is of great interest to the journal. Several categories of manuscripts (for detailed description see below) are considered: editorials, original articles (also including randomized clinical trials, systematic reviews and meta-analyses), reviews (narrative reviews), opinion articles (including debates, perspectives and commentaries); and letters to the Editor.